TY - JOUR
T1 - Analytical methods to monitor dopamine metabolism in plasma
T2 - moving forward with improved diagnosis and treatment of neurological disorders
AU - Dias, Ana Sofia Abrantes
AU - Pinto, Joana Catarina Amaral
AU - Magalhães, Mariana
AU - Mendes, Vera M.
AU - Manadas, Bruno
N1 - Funding Information:
This work was financed by the European Regional Development Fund (ERDF) through the COMPETE 2020 - Operational Programme for Competitiveness and Internationalization and Portuguese national funds via FCT – Fundação para a Ciência e a Tecnologia , I.P., OE FCT/MCTES (PIDDAC) under projects: POCI-01-0145-FEDER-029311 (ref.: PTDC/BTM-TEC/29311/2017), POCI-01-0145-FEDER-007440 (UIDB/04539/2020), POCI-01-0145-FEDER-016428 (ref.: SAICTPAC/0010/2015), POCI-01-0145-FEDER-016795 (ref.: PTDC/NEU-SCC/7051/2014), POCI-01-0145-FEDER-30943 (ref.: PTDC/MEC-PSQ/30943/2017), POCI-01-0145-FEDER-029311 (PTDC/BTM-TEC/29311/2017), and PTDC/MED-NEU/27946/2017; and by the National Mass Spectrometry Network (RNEM) under the contract POCI-01-0145-FEDER-402-022125 (ref.: ROTEIRO/0028/2013).
Publisher Copyright:
© 2020 Elsevier B.V.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8/5
Y1 - 2020/8/5
N2 - Since dopamine (DA) was discovered as an essential neurotransmitter, with a profound impact on motor control, memory, and behavioral impulses, the pathogenesis of several neurodegenerative and neuropsychiatric disorders have been associated with the dysfunction of the dopaminergic system. Regarding this, the most common drugs used to treat these pathologies act on the dopaminergic neurons. Therefore, the measurement of DA and its precursors and metabolites levels can be a useful tool to help the diagnosis and development of targeted therapeutic approaches to neurological disorders. Furthermore, monitoring and detecting DA metabolism (DA, precursors, and metabolites) in biological samples, like plasma, urine, and cerebrospinal fluid, constitute an interesting subject from a clinical perspective. However, the development of suitable and efficient methods to determine these compounds in biological samples remains a challenge. Thus, this review provides an overview of the recent advances and available methodologies to quantify DA and its precursors and metabolites in plasma samples focusing on previous reports which used less than two milliliters. Also, it deals with the actual extraction and separation techniques, as well as detection modes; and it gives a perspective, on the present-day, about the use of analytical methods as a helpful tool to improve diagnosis.
AB - Since dopamine (DA) was discovered as an essential neurotransmitter, with a profound impact on motor control, memory, and behavioral impulses, the pathogenesis of several neurodegenerative and neuropsychiatric disorders have been associated with the dysfunction of the dopaminergic system. Regarding this, the most common drugs used to treat these pathologies act on the dopaminergic neurons. Therefore, the measurement of DA and its precursors and metabolites levels can be a useful tool to help the diagnosis and development of targeted therapeutic approaches to neurological disorders. Furthermore, monitoring and detecting DA metabolism (DA, precursors, and metabolites) in biological samples, like plasma, urine, and cerebrospinal fluid, constitute an interesting subject from a clinical perspective. However, the development of suitable and efficient methods to determine these compounds in biological samples remains a challenge. Thus, this review provides an overview of the recent advances and available methodologies to quantify DA and its precursors and metabolites in plasma samples focusing on previous reports which used less than two milliliters. Also, it deals with the actual extraction and separation techniques, as well as detection modes; and it gives a perspective, on the present-day, about the use of analytical methods as a helpful tool to improve diagnosis.
KW - Analytical methods
KW - Dopamine
KW - Neurological disorders
KW - Plasma
UR - http://www.scopus.com/inward/record.url?scp=85085476273&partnerID=8YFLogxK
U2 - 10.1016/j.jpba.2020.113323
DO - 10.1016/j.jpba.2020.113323
M3 - Review article
C2 - 32470692
AN - SCOPUS:85085476273
SN - 0731-7085
VL - 187
JO - Journal of Pharmaceutical and Biomedical Analysis
JF - Journal of Pharmaceutical and Biomedical Analysis
M1 - 113323
ER -